NASDAQ:NRBO - Nasdaq - US64132R4048 - Common Stock - Currency: USD
Overall NRBO gets a fundamental rating of 2 out of 10. We evaluated NRBO against 558 industry peers in the Biotechnology industry. NRBO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRBO does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -125.23% | ||
ROE | -214.1% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -10.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.41 | ||
Quick Ratio | 2.41 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:NRBO (11/27/2024, 8:56:43 PM)
2.36
+0.01 (+0.43%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.57 | ||
P/tB | 1.57 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -125.23% | ||
ROE | -214.1% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 85.71% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.41 | ||
Quick Ratio | 2.41 | ||
Altman-Z | -10.54 |